Caplin Point Laboratories share news, announcements and annual reports
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Caplin Point Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1995 on BSE, Jun 2014 on NSE
Last close ₹2,362.80up ₹10.40 (0.44%)BSE ₹2,362.55
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,352.40.
28 Oct: open ₹2,352.00, high ₹2,377.10, low ₹2,330.00
52-week range of traded prices to 28 Oct 2026
₹1,500.30Low, 30 Mar 2026₹2,990.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,960 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.01
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 39,48950.3% delivered
Caplin Point Laboratories board and management
39 filed, newest first.
Aug 2026
12 Aug · Management
Mar 2026
Feb 2026
3 Feb · Management
Nov 2025
Sep 2025
22 Sep · Management
Jul 2025
Jun 2025
27 Jun · Management
May 2025
Apr 2025
Nov 2024
Sep 2024
Aug 2024
7 Aug · Management
Jun 2024
11 Jun · Management
Dec 2023
14 Dec · Management
Sep 2023
21 Sep · Management
Aug 2023
14 Aug · Management
May 2023
Sep 2022
Jul 2022
Jun 2022
May 2021
6 May · Management
Feb 2021
Oct 2019
30 Oct · Management
Apr 2019
May 2018
8 May · Management
Mar 2018
Feb 2018
7 Feb · Management
Nov 2016
May 2016
Feb 2016
May 2015
Apr 2015
Feb 2015
Aug 2014
26 Aug · Management
Mr. Sridhar Ganesan, an Independent Director in the Board of the Company has resigned with effect from August 25, 2014, as the Board has requested Mr. Sridhar Ganesan to involve in the affairs of the Company on a whole time basis. Hence, Mr. Sridhar Ganesan would be functioning as a Whole Time Director of the Company with effect from August 25, 2014.26 Aug · Management
Dr. K C John is appointed as an Independent Director by the Board of the Company with effect from 25th August, 2014.